Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 1.00 |
| ▸ | CA9 | Q16790 | 9/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 0.75 |
| ▸ | NPC1 | O15118 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | ELANE | P08246 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11142139 | 0.86 | RAB9A (1.00) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL10908945 | 0.85 | CA12 (1.00) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL13606224 | 0.83 | CA12 (0.76) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL11601021 | 0.82 | NPC1 (1.00) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL9168762 | 0.82 | RAB9A (0.86) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL11711641 | 0.81 | CA12 (0.75) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL11144818 | 0.81 | RAB9A (0.84) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL356403 | 0.81 | CA12 (0.69) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL6611636 | 0.81 | CA12 (0.68) | CA12CA9CA2RAB9ANPC1 | |
| SCHEMBL23185354 | 0.80 | CA12 (0.78) | CA12CA9CA2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4471790-B1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MICROBIOTX HEALTH PRIVATE LTD (IN) | 2026-04-01 | — | — | EP | disclosed |
| CN-119409661-A | Method for preparing non-steroidal anti-inflammatory drug intermediate in ester solvent | 苏州天马医药集团天吉生物制药有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4471790-A1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MicrobioTx Health Private Limited (IN) | 2024-12-04 | — | — | EP | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-9937167-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057013-A2 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-25 | — | — | WO | disclosed |
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2009-12-17 | — | — | US | disclosed |
| US-5051510-A | Piperidine derivatives as antihistaminics | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMECEUTI-COS S.A. (FAES) (ES) | 1991-09-24 | — | — | US | disclosed |
| EP-0146102-B1 | PROCESS FOR PREPARING BENZOTHIAZINE COMPOUNDS | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1989-03-01 | — | — | EP | disclosed |
| US-4797483-A | Process for obtaining 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | INDUSPOL, S.A. (ES) | 1989-01-10 | — | — | US | disclosed |
| US-4599406-A | ANHYDRIDING, AMIDATION, ANTIINFLAMMATORY AGENTS | SPA-SOCIETA PRODOTTI ANTIBIOTICI SPA (IT) | 1986-07-08 | — | — | US | disclosed |
| EP-0146102-A2 | Process for preparing benzothiazine compounds | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1985-06-26 | — | — | EP | disclosed |
| US-4116964-A | 2-[(N-2-pyridylcarbamoyl)methyl]saccharin | WARNER-LAMBERT COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4074048-A | Process for the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides | WARNER-LAMBERT COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | CA12 3053/4885CA9 1485/4885CA2 1512/4885 |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | CA12 4880/4885CA9 4861/4885CA2 4795/4885 |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CA12 4880/4885CA9 4861/4885CA2 4795/4885 |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3A, PDE4B | CA12 4495/4885CA9 2260/4885CA2 1813/4885 |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CA12 4880/4885CA9 4861/4885CA2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.